Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Blood Année : 2021

Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy

(1) , (2) , (3) , (4) , (5) , (6) , (7) , (8, 6) , (9) , (10) , (11, 12) , (13, 14) , (15) , (16) , (17) , (11) , (18) , (19, 20) , (21) , (22) , (23) , (24) , (11) , (20) , (25) , (6) , (4) , (11) , (26) , (6)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
Celine Berthon
Thomas Cluzeau
  • Fonction : Auteur

Résumé

To design a simple and reproducible classifier predicting the overall survival (OS) of patients with acute myeloid leukemia (AML) >= 60 years of age treated with 7+3, we sequenced 37 genes in 471patients fromtheALFA1200 (Acute Leukemia FrenchAssociation) study (median age, 68 years). Mutation patterns and OS differed between the 84 patients with poor-risk cytogenetics and the 387 patientswith good (n = 13), intermediate (n = 339), or unmeasured (n = 35) cytogenetic risk. TP53 (hazards ratio [HR], 2.49; P = .0003) and KRAS (HR, 3.60; P = .001) mutations independently worsened the OS of patients with poor-risk cytogenetics. In those without poor-risk cytogenetics, NPM1 (HR, 0.57; P = .0004), FLT3 internal tandem duplications with low (HR, 1.85; P = .0005) or high (HR, 3.51; P < 10(-4)) allelic ratio, DNMT3A (HR, 1.86; P < 10(-4)), NRAS (HR, 1.54; P = .019), and ASXL1 (HR, 1.89; P=.0003) mutations independently predicted OS. Combining cytogenetic risk and mutations in these 7 genes, 39.1% of patients could be assigned to a ``go-go'' tier with a 2-year OS of 66.1%, 7.6% to the ``no-go'' group (2-year OS 2.8%), and 3.3% of to the ``slow-go'' group (2-year OS of 39.1%; P < 10(-5)). Across 3 independent validation cohorts, 31.2% to 37.7% and 11.2% to 13.5% of patients were assigned to the go-go and the no-go tiers, respectively, with significant differences inOS between tiers in all 3 trial cohorts (HDF [Hauts-de-France], n = 141, P = .003; andSAL [StudyAlliance Leukemia], n=46; AMLSG [AML Study Group], n = 223, both P < 10(-5)). The ALFA decision tool is a simple, robust, and discriminant prognostic model for AML patients >= 60 years of age treated with intensive chemotherapy. This model can instruct the design of trials comparing the 7+3 standard of care with less intensive regimens.

Dates et versions

hal-03606388 , version 1 (11-03-2022)

Identifiants

Citer

Raphael Itzykson, Elise Fournier, Celine Berthon, Christoph Rollig, Thorsten Braun, et al.. Genetic identification of patients with AML older than 60 years achieving long-term survival with intensive chemotherapy. Blood, 2021, 138 (7), pp.507-519. ⟨10.1182/blood.2021011103⟩. ⟨hal-03606388⟩
22 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook Twitter LinkedIn More